Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy Mar 20, 2025
Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook Feb 19, 2025
Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast Jan 31, 2025
Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment Jan 20, 2025
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan Jan 20, 2025
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook Dec 9, 2024
